Volume 17 Supplement 2
Continuous arterial and venous glucose monitoring by quenched chemical fluorescence in ICU patients after cardiac surgery
© Bird et al.; licensee BioMed Central Ltd. 2013
Published: 19 March 2013
Continuous glucose monitoring (CGM) in ICUs has the potential to improve patient safety outcomes. The GluCath Intravascular CGM System uses a novel quenched chemical fluorescence sensing mechanism to measure glucose concentration in venous or arterial blood (BG). This is the first report of this system deployed for 48 hours in both arteries and veins of ICU patients.
This ongoing clinical study evaluates up to two sensors per subject in 20 patients undergoing cardiac surgery. An arterial sensor is deployed via a standard 20 G radial artery catheter inserted for routine care and an optional venous sensor is deployed percutaneously in an upper arm vein. Data are presented from the first five patients. Outcome measures are qualitative (ease of use, workflow fit) and quantitative (accuracy vs. reference analyzer). Sensors were inserted shortly after ICU admission, with ultrasound guidance for venous sensor insertion. In vivo calibration was performed at 1 and 2 hours, then each morning. Glucose values were recorded every 10 seconds by the system. Hourly arterial reference samples were analyzed via Radiometer ABL 800 Flex Blood Gas Analyzer (BGA).
The GluCath System measured glucose concentration continuously in cardiac surgery ICU patients. Arterial catheter deployment did not appear to compromise line function or patient care. Percutaneous venous deployment was feasible, but may be associated with risk of local venous thrombosis.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.